Is Supriya Lifesci. overvalued or undervalued?

As of 24 July 2025, the valuation grade for Supriya Lifesci. has moved from very expensive to expensive, indicating a slight improvement in its valuation perception. The company appears to be overvalued based on its current metrics, with a PE ratio of 29.63, an EV to EBITDA ratio of 21.05, and a PEG ratio of 0.51. These ratios suggest that while the company has strong fundamentals, its valuation does not align favorably with its earnings growth potential.
When compared to peers, Supriya Lifesci.'s PE ratio is significantly higher than Cipla's attractive PE of 22.81 and Dr. Reddy's Labs' attractive PE of 18.58. Additionally, the company's EV to EBITDA ratio of 21.05 is also higher than the industry average, further reinforcing the notion of overvaluation. Despite a strong one-year stock return of 80.15% compared to the Sensex's 2.54%, the current valuation metrics indicate that Supriya Lifesci. may not provide a compelling investment opportunity at this time.